Molecular Analysis of a Myxoid Chondrosarcoma with Rearrangements of Chromosomes 10 and 22

Wei-Ping V. Shen, Ronald F. Young, Barbara N. Walter, Byung H. Choi, Moyra Smith, and Jacob Katz

ABSTRACT: Myxoid chondrosarcoma is a rare tumor of adulthood. An associated nonrandom reciprocal translocation between chromosome 9 and 22 was previously reported in this tumor. We performed cytogenetic and molecular genetic analysis of a myxoid chondrosarcoma derived from the sphenoid bone. Using restriction fragment length polymorphism (RFLP) analysis, we demonstrated rearrangement and a possible allele loss close to the chromosome 22 breakpoint. In addition, structural rearrangement in the chromosome 10q21.1 region and an allele loss in the chromosome 10q21-q23 region were also detected. In tumor DNA an additional hybridization fragment was detected by pAS-1 probe, which recognizes multiple pseudogenes of argininosuccinate synthetase dispersed in various chromosomes. We were unable to detect chromosomal abnormalities with two additional chromosome 9q probes. This study suggests that multiple gene rearrangements occurred in the myxoid chondrosarcoma and the significance of this is discussed.

INTRODUCTION

Identification of the specific cytogenetic abnormalities in cancers is important in disease diagnosis, defining tumor subtypes as well as providing the clue to the location of the genes involved in formation of the tumors. Nonrandom structural chromosome abnormalities have been identified in various soft tissue sarcomas [1]. Reciprocal translocation between chromosome 9 and 22 has been reported in two rare myxoid chondrosarcomas [2, 3]. Recently, molecular analysis was used to study the genotype of solid tumors. The molecular genetic study can be performed directly on the tumor tissue and avoids the possible secondary change occurring in in vitro propagation. The method can detect small chromosome deletions and rearrangements beyond the resolution of cytogenetic study. We performed molecular analysis of a sphenoid myxoid chondrosarcoma. In this tumor, rearrangement and a possible allele loss were detected in the chromosome 22q11-q12 region with the DNA probes and were consistent with the previous cytogenetic observation. We also demonstrated rearrangement and allele loss on chromosome 10.

From the Divisions of Pediatric Hematology-Oncology (W.-P. V. S., B. N. W., J. K.), Neurosurgery (R. F. Y.), Neuropathology (B. H. C.), and Pediatric Genetics (M. S.) University of California, Irvine, California.

Address reprint requests to: Dr. Wei-Ping V. Shen, Department of Pediatrics, Building 27, Rt. 81, UCI Medical Center, 101 City Dr., Orange, CA 92668.

Received April 10, 1989; accepted August 7, 1989.

© 1990 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

Cancer Genet Cytogenet 45:207–215 (1990)
CASE REPORT

A 27-year-old white woman was admitted in March 1987 with the chief complaint of right-sided vision and hearing loss and right facial numbness. Computerized tomography and magnetic resonance imaging scans of the head showed the presence of a large mass at the right frontotemporal region. A large encapsulated tumor mass, very mucoid and with focal calcification, was surgically removed. The major histologic constituent was a mildly to moderately cellular neoplasm composed of small to medium-sized polyhedral cells with bright pink cytoplasm and small, rounded, single or multiple nucleolated nuclei (Fig. 1). The pathologic diagnosis was chordosarcoma of the right sphenoid ring. Two years after operation the patient is alive without recurrence.

MATERIALS AND METHODS

Isolation of DNA and RFLP Analysis

Tumor that had been frozen on dry ice at the time of removal and stored at -70°C was used for DNA isolation. The frozen tumor was pulverized in liquid nitrogen and then suspended in a lysis buffer containing 20 mM Tris-HCl, 1 mM EDTA, 1% sodium dodecylsulfate (SDS) and 100 μg/ml proteinase K and incubated at 37°C up to 18 hours. DNA was then extracted with phenol-chloroform-isooamyl alcohol (CHISM) and precipitated with 0.4 M ammonium-acetate and cold ethanol. The DNA pellets were dissolved in Tris-EDTA buffer. The patient’s lymphocyte DNA was used as a control. Mononuclear cells isolated from the peripheral blood were resuspended in 10 mM Tris and then lysed with lysis buffer and extracted as above.

Ten micrograms of the control and the tumor DNA were digested to completion with the appropriate restriction enzymes, fractionated by 0.8% agarose gel electrophoresis, and transferred to Gene Screen plus nylon membrane according to the manufacturer’s protocol. Prehybridization and hybridization were performed in a solution containing 1% SDS, 1 M NaCl, 10% dextran sulfate, 0.05 M Tris pH 7.5, and 0.5 mg/ml denatured herring sperm DNA at 65°C with shaking. The probe was radioabeled with 32P-ATP by random oligonucleotide primer procedure [4]. Filters were washed twice in 2x SSC/0.1% SDS at room temperature, once in 1 x SSC/0.1% SDS for 15 minutes, and once in 0.1 x SSC/0.1% SDS at 60°C for 30 minutes. Autoradiography was performed using Kodak XAR-5 film with intensifying screen at -70°C overnight or for several days depending on the particular probe used.

RFLP probes used in this study included D22S1 (Dr. Y. Nakamura); D22S9 and D10S5, (Dr. B. N. White); c-sis, HoxII, D10S1, D10S4 and NGF-B (American Tissue Type Collection); pAS-1 (Dr. A. L. Beaudet), and Aldo-B (Dr. F. Salvatore).

Determination of Allelic Dosage

BglII blot hybridized with the D22S1 probe was stripped in 0.4N NaOH at 65°C for 30 minutes followed by 0.1 x SSC, 0.1% SDS, and 0.2 M Tris-HCl pH 7.5 at 65°C for 30 minutes and was rehybridized with NGF-B. TaqI blot was hybridized with D22S9, stripped in the same fashion and rehybridized with the D10S4 and D10S5 probes. HindIII blot was used for both pAS-1 and D10S5 probes. The stripped blot was checked with an autoradiogram before reuse. The intensity of the hybridization signals were determined by laser densitometry (LKB ultrascan XL), and peak areas corresponding to each hybridization signal were calculated by electronic integration.
Figure 1  a) Tightly packed tumor cells in close proximity to cancellous bone (arrow). Loosely organized tumor cells show myxoid appearance (open arrow) (Hematoxylin and eosin ×88.) b) Highly cellular region of tumor; tumor cells have small, rounded, and vesicular nuclei. (Hematoxylin and eosin ×88.) c) Myxoid appearance of tumor cells (open arrow) with small to moderate amount of pink cytoplasm. (Hematoxylin and eosin ×220.) d) Higher magnification of tumor cells showing nuclear pleomorphism and hyperchromatism (open arrow) and occasional mitotic figures (arrow). (Hematoxylin and eosin ×440.) e) Higher magnification of the tumor cells showing cartilagenous differentiation (open arrow) and hyperchromatic nuclei of the pleomorphic tumor cells. (Hematoxylin and eosin ×440.) f) Higher magnification of tumor cells shows moderate to marked pleomorphism of nuclei with hyperchromatism (open arrow). (Hematoxylin and eosin ×440.)
RESULTS

Rearrangement Detected at Locus on Chromosome 22

The tumor and control DNA were compared with three RFLP probes on chromosome 22. D22S1 is an anonymous genomic DNA segment mapped to 22q11-22q13 that gives rise to two RFLP alleles with the BgIII restriction enzyme. D22S9 is an anonymous RFLP probe mapped to 22q11. c-sis is a protooncogene (PDGF-B chain) that detects two RFLP alleles with a HindIII digestion (Fig. 2). The results are shown in Fig. 3 and summarized in Table 2. The control DNA was homozygous for D22S9 and had a 5.8-kilobase (kb) hybridization signal with TaqI digestion; the tumor DNA displayed an extra hybridization signal at 5.2 kb, suggesting that the tumor DNA had a possible small internal deletion or rearrangement of one allele in the region of chromosome 22q11. Analysis of control DNA with the D22S1 probe revealed homozygous hybridization signal at 9.5 kb. A marked decrease in allele signal intensity was observed in the tumor sample, indicating a possible hemizygous deletion of chromosome 22 sequences in the tumor cells. This was supported by rehybridizing the same DNA blot with NGF-b probe (mapped to chromosome 1); both tumor and constitutional DNA had hybridization signals that were of equal intensity. Densitometry analysis is shown in Table 1. No loss of heterozygosity was detected with the c-sis probe.
Figure 3  Allele loss and structural changes were detected with various chromosome 22 and 10 probes in a myxoid chondrosarcoma. Probes and restriction enzymes used are indicated beneath each normal (N)/tumor (T) pair. Numbers on left indicate sizes of RFLP alleles; arrows on right indicate aberrant bands.

Loss of Heterozygosity and Rearrangement at Loci on Chromosome 10

The tumor and control DNA were compared with three chromosome 10 RFLP probes: D10S4, D10S5, and D10S1. The chromosomal localization of these probes is shown in Fig. 2. Control DNA was heterozygous at D10S4 locus and yielded 7.4 kb and 4.9 kb bands, whereas tumor DNA retained only a 7.4-kb band. An aberrant band was observed only in the tumor DNA with D10S5 probe using three different enzymes.

Table 1  Densitometric analysis of allelic signals

|        | D22S1 | NGF-b | Ratio [D22S1/NGF] |
|--------|-------|-------|-------------------|
| Tumor  | 0.96  | 6.06  | 0.16              |
| Normal | 2.30  | 8.58  | 0.27              |

Comparison of the signal responses produced by D22S1 probe and NGF-b (located on chromosome 1) in both tumor DNA and control DNA.

The numbers in this table represent area of peak density of the hybridization signal measured by LKB ultrascan densitometer. The normalized tumor to normal DNA value at the D22S1 locus was close to 1/2 and suggests that the tumor may have a partial deletion at this region.
Table 2 Allele loss and structural changes detected with various chromosome 22 and 10 probes in a myxoid chondrosarcoma

| Chromosome | Probe     | Enzyme | Normal | Tumor |
|------------|-----------|--------|--------|-------|
| 22         | D22S9     | Taq I  | H      | A     |
| 22         | D22S1     | Bgl II | H      |       |
| 22         | c-sis     | Hind III | 1.2   | 1.2   |
| 10         | D10S4     | Taq I  | 1.2    |       |
| 10         | D10S5     | Taq I  | H      |       |
| 10         | D10S5     | Hind III | H     |       |
| 10         | D10S5     | Hinc II | H     |       |
| 9          | Aldo-B    | Pvu-2 | H      | H     |
| 9          | abl-3     | Taq I  | H      | H     |
| ?          | pAS-1     | Hind III | H     | A     |
| 1          | NGF-b     | Bgl II | 1.2   | 1.2   |
| 17         | Hox-II    | Sac I | H      | H     |

Abbreviations: 1, presence of the larger allele restriction fragment and loss of the smaller allele.
1.2, heterozygosity present. A, presence of aberrant restriction fragment other than RFLP allele.
H, homozygous for the probe tested.

RFLP Analysis of Loci on Other Chromosomes

A breakpoint in the 9q31 and 22q12.2 regions was previously reported in two myxoid chondrosarcomas [1]. We studied tumor and control DNA with chromosome 9q RFLP probes including pAS-1 (cDNA for argininosuccinate synthetase enzyme; sequence showed that RFLP mapped to 9q11-q22) and Aldo B (mapped to 9q21.3 to q32). The tumor and the control DNA were homozygous for Aldo B probe as well as pAS-1 probe. Tumor DNA had an extra 2.4-kb hybridization signal with pAS-1 probe, however, displayed decreased signal intensity with a 2.1-kb band (Fig. 4). Multiple pseudogenes for human argininosuccinate synthetase are dispersed in multiple autosomes, and the X chromosome pAS-1 detects one argininosuccinate synthetase pseudogene mapped in the 9q11-q22 region and the argininosuccinate synthetase structural gene mapped in the 9q34 region [5, 6]. Pseudogenes on chromosome 9q11-q22 give HindIII polymorphism 3.9 kb and 2.7 kb. The 2.1-kb band is derived from the chromosome 12 argininosuccinate synthetase pseudogene (mapped to 12p13-qter). Hence the extra 2.4-kb band may be derived from the chromosome 12. The abl oncogene probe (located at 9q34) did not show a difference between tumor and control DNA. Both tumor and control DNA were homozygous for HoxII (chromosome 17) probe and heterozygous for NGF-B probe (chromosome 1).

DISCUSSION

Hinrichs et al. [2] reported a case of myxoid chondrosarcoma of the right shoulder with a nonrandom reciprocal translocation t(9;22)(q22;q11). Turc-Carel et al. [3] subsequently reported another case of extraskeletal myxoid chondrosarcoma from the left distal thigh with a clonal translocation t(9;15;22) (q31;q25;q12.2) and suggested that breakpoints 9q31 and 22q12.2 were associated with extraskeletal myxoid chondrosarcoma. Our case had abnormalities involving the 22q11-q23 region, as demonstrated.
Figure 4  Comparison of hybridization patterns of HindIII-digested DNA from normal and tumor tissue with pAS-1 probe. Tumor DNA exhibited an extra 2.4-kb band. The pAS-1 probe recognized one expressed gene and 14 pseudogenes of argininosuccinate synthetase dispersed on 11 different chromosomes. The 3.9-kb and 1.4-kb bands were derived from argininosuccinate synthetase pseudogenes on chromosome 9; the 2.5-kb band was derived from chromosome 7, and the 1.9-kb band was derived from chromosome 5. The 2.1-kb band derived from chromosome 12 was significantly weaker in tumor DNA.

by RFLP analysis of the tumor and the constitutional DNA. Two different chromosome 10 probes have detected abnormalities in the tumor DNA, one showing allele loss in 10q21-q23 region and the other showing a possible internal deletion or rearrangement at 10q21.1 region. Three chromosome 9q probes were used to detect molecular evidence of rearrangement; no differences were observed with the aldolase B probe (mapped to 9q21-32) and abl probe (9q34). pAS-1 probe revealed an aberrant band, however, owing to dispersed chromosome location of multiple argininosuccinate synthetase pseudogene, this aberrant band may not be derived from the chromosome 9. In addition a decreased hybridization signal of chromosome 12 argininosuccinate synthetase pseudogene derived sequence was observed. Because the rearrangement may not be detected by standard Southern analysis, the negative data on chromosome 9 do not exclude the possible involvement of chromosome 9 in myxoid chondrosarcoma. No abnormality was detected with probes from chromosome 1 and 17.

Loss of heterozygosity or hemizygous deletion at a specific chromosome locus often indicates that chromosomal deletions have occurred; such deletions may also be accompanied by chromosomal rearrangement. In certain tumors, deletions in a particular gene region led to identification of a recessive cancer gene or tumor suppres-
The first characterized tumor suppressor gene-retinoblastoma gene (Rb) [8] is deleted or mutated not only in retinoblastomas but also in osteogenic sarcomas, small cell lung carcinomas, breast cancers, and bladder cancers [9–12]. DNA rearrangement can move a cellular protooncogene adjacent to another oncogene or into an active transcription unit and result in increased production or production of an altered gene product involved in cell growth. This has been best illustrated in chronic myelogenous leukemia (CML) and Burkitt's lymphoma [13, 14].

The present study demonstrates allele loss, rearrangement, or a small deletion involving chromosomes 10 and 22 occurring in a rare sporadic myxoid chondrosarcoma, a tumor of mesenchymal origin. Cytogenetic and molecular genetic abnormalities involving chromosome 22q11-q22 have been reported in various neuroectodermal tumors [eg, meningioma, Ewing's sarcoma, peripheral neuroepithelioma, acoustic neuroma, and astrocytoma [15–19]]. Loss of chromosome 10 is also commonly found in high-grade gliomas and meningiomas [20, 21] implicating a possible common molecular mechanism involved in the evolution of these neoplasms. The marker D10S5 showing rearrangement in this tumor is linked to multiple endocrine neoplasia (MEN) 2A locus with a maximum lod score of 3.58 at a recombination frequency of 0.19 [22]. Patients with MEN 2 are predisposed to develop medullary thyroid cancer, pheochromocytoma, and parathyroid adenoma. These findings suggest the presence of genes closed to D10S5 locus and chromosome 22q11-q22 region involved in the tumorigenesis. To determine whether chromosome 10 and 22 abnormalities are specific for myxoid chondrosarcoma, more tumors need to be studied with similar probes. Detailed mapping of the chromosome 22q11-12 region and the chromosome 10q21.1 region may reveal genes involved in the formation of this rare tumor and possible other more common tumors.

The authors thank Drs. B. N. White, R. White, Y. Nakamura, A. L. Beaudet, and F. Salvatore for providing the DNA probes used in this study. This work is supported by the Concern I foundation for cancer research.

REFERENCES

1. Sandberg AA, Turc-Carel C, Gemmill RM (1988): Chromosomes in solid tumors and beyond. Cancer Res 48:1049–1059
2. Hinrichs SH, Jaramulo MA, Gumerlock PH, Gardner MB, Lewis JP, Freeman AE (1985): Myxoid chondrosarcoma with a translocation involving chromosome 9 and 22. Cancer Genet Cytogenet 14:219–226
3. Turc-Carel C, Cin PD, Rao U, Karakousis C, Sandberg AA (1988): Recurrent breakpoint at 9q31 and 22q12 in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 30:145–150.
4. Feinberg AP, Volgelstein B (1983). A technique for radiolabeling DNA restriction endonuclease fragment to high specific activity. Anal Biochem 132:6–13.
5. Daiger SP, Hoffman N, Wildin RS, Su TS (1984). Multiple, independent restriction site polymorphisms in human DNA detected with a cDNA probe to argininosuccinate synthetase (AS). Am J Hum Genet 36:736–749
6. Su TS, Nussbaum RL, Airhart S, Ledbetter DH, Mohandas T, O'Brien WE, Beaudet AL (1984). Human chromosomal assignment for 14 argininosuccinate synthetase pseudogenes: Cloned DNAs as reagents for cytogenetic analysis. Am J Hum Genet 36:954–964
7. Klein G (1987). The approaching era of the tumor suppressor genes. Science 238:1539–1545.
8. Friend SH, Bernard R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986): A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646.
9. Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, Gedde-Dahl T, Cavenee
WK (1985): Osteosarcoma and retinoblastoma: A shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82:6216–6220.

10. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988): Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353–357.

11. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH (1988): Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218.

12. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, Harlow ED, Weinberg RA, Dryja TP (1989): Point mutational inactivation of the retinoblastoma antioncogene. Science 243:937–939.

13. de Klein A, van Kessel AG, Grosveld AG, Bartram CR, Hagemeljer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR (1982): A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765–768.

14. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P (1982): Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837–7841.

15. Zang K (1982): Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6:249–274.

16. Turc-Carel C, Philip I, Berger M, Philip T, Lenoir GM (1983): Chromosomal translocations in Ewing's sarcoma. N Engl J Med 309:497–498.

17. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA (1984): Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 311:584–585.

18. Seizinger BR, Martuza RL, Guesella JF (1986): Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322:644–647.

19. Bigner SH, Mark J, Burger PC, Mahaley MS, Bullard DE, Muhlbaier LH, Bigner DD (1988): Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 48:405–411.

20. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK (1988): Clonal genomic alterations in glioma malignancy stages. Cancer Res 48:5546–5551.

21. Seizinger BR, De la Monte S, Atkins L, Guesella JF, Martuza RL (1987): Molecular genetic approach to human meningioma: Loss of genes on chromosome 22. Proc Natl Acad Sci USA 84:5419–5423.

22. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan MV, Farrer LA, Brasch K, Castiglione C, Genel M, Gertner J, Greenberg CR, Guesella JF, Holden JJA, White BN (1987): Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328:528–530.